Recently, biotech company DanCann Pharma signed a Letter of Intent with Canadian Tetra Bio-Pharma for the exclusive distribution rights for cannabionoid-based drugs in the Nordic region as well as in Europe’s largest pharmaceutical market – Germany. DanCann’s board member, Per Wester, visited BioStock’s studio to chisel out the significance of this agreement and talk about the visions for the future.
Watch the interview with DanCann Pharma’s board member Per Wester below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.